| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 05/16/2007 | CN1961938A Pharmaceutical composition for treating angina pectoris and preparation method thereof |
| 05/16/2007 | CN1961937A Ointment for moving blood, resolving stasis, reducing swelling and easing pain and preparation process thereof |
| 05/16/2007 | CN1961928A Blood circulation-activating stasis-removing medicament for treating blood stasis syndrome and preparation process thereof |
| 05/16/2007 | CN1961924A Treatment of cardiac insufficiency and cardiac failure by using 'Shen Gui' capsule |
| 05/16/2007 | CN1961916A Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof |
| 05/16/2007 | CN1961911A Lyophilized powder injection containing red sage root and dalbergia wood volatile oil and preparation method thereof |
| 05/16/2007 | CN1961904A Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof |
| 05/16/2007 | CN1961900A Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof |
| 05/16/2007 | CN1961897A Method for verifying pomegranate rind extract |
| 05/16/2007 | CN1961892A Dalbergia wood and beta-cyclodextrin inclusion compound, formulation thereof and preparation method thereof |
| 05/16/2007 | CN1961883A Use of ferriporphyrin short peptide compound in preparation of medicament for resisting coronary heart disease |
| 05/16/2007 | CN1961876A Use of phthalimide derivative in preparation of medicament for resisting angiogenesis |
| 05/16/2007 | CN1961870A Method for preparing sustained releasing microcapsule of phenoxybenzamine hydrochloride and ethyl cellulose |
| 05/16/2007 | CN1961869A Orally disintegrating tablet of coenzyme Q10 and preparation method thereof |
| 05/16/2007 | CN1315866C Radix asparagi steroid saponin extract and its preparing process and application |
| 05/16/2007 | CN1315847C 1-thia-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof |
| 05/16/2007 | CN1315840C Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives used as drug for treating pain |
| 05/16/2007 | CN1315835C Polycyclic guanine phosphodiesterase v inhibitors |
| 05/16/2007 | CN1315833C Azaindole kinase inhibitors |
| 05/16/2007 | CN1315832C Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl-6,7,8,9-tetrahydropydimido[1,2-a]pyrimidin-4-one derivatives |
| 05/16/2007 | CN1315827C 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands |
| 05/16/2007 | CN1315822C Quinoline derivatives having VEGF inhibiting activity |
| 05/16/2007 | CN1315813C 2-amino-4h-3,1-benzoxazin-4-one derivatives for the treatment of obesity |
| 05/16/2007 | CN1315806C Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors |
| 05/16/2007 | CN1315803C Aminopyridyl-substituted phenyl acetamides as protease inhibitors |
| 05/16/2007 | CN1315495C Danshen root extract, production, medicine preparation and inspection thereof |
| 05/16/2007 | CN1315481C Ginkgo leaf extract and its extracting method |
| 05/16/2007 | CN1315473C Therapeutic compositions |
| 05/16/2007 | CN1315463C Guanxinning drip pill for treating heart disease and its preparation method |
| 05/16/2007 | CN1315458C Compound tall gastrodia tuber preparation and production thereof |
| 05/15/2007 | USRE39634 treatment of neuropathic pain; elevate levels of anandamide or other endogenous cannabinoids to increase the nociceptive threshold |
| 05/15/2007 | US7217832 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation |
| 05/15/2007 | US7217826 Making intermediates to alpha-ethyl-2-oxo-1-pyrrolidine acetamide, also referred to as levetiracetam an antihypoxic agent and antiischemic agent; by reduction via catalytic hydrogenation of an alkenyl intermediate |
| 05/15/2007 | US7217800 Peptide leukotriene receptor |
| 05/15/2007 | US7217796 Neutralizing human anti-IGFR antibody |
| 05/15/2007 | US7217786 Polypeptide ESDN, polynucleotides encoding the polypeptide, and utility of the polypeptide |
| 05/15/2007 | US7217734 Substituted benzopyrans as selective estrogen receptor-beta agonists |
| 05/15/2007 | US7217733 Cardiovascular disorders; kidney disorders; antiinflammatory agents |
| 05/15/2007 | US7217732 Cannabinoid receptor agonists |
| 05/15/2007 | US7217728 For therapy of reperfusion injury |
| 05/15/2007 | US7217719 1,3,8-Triaza-spiro[4.5]decan-2-one compounds, e.g., (4S)/(4R)-4-(4-Fluorobenzyl)-3-(4-isobutoxybenzyl)-8-methyl-1,3,8-triaza-spiro [4.5]decan-2-one; treating schizophrenia, psychosis, migraine, hypertension, thrombosis, vasospasm, depression, anxiety, sleep and eating disorders |
| 05/15/2007 | US7217710 Pyrazolo-pyrimidine compound; anticancer agents |
| 05/15/2007 | US7217708 3,7-Diazabicyclo [3.3.1] formulations as anti-arrhythmic compounds |
| 05/15/2007 | US7217701 Intracellular calcium concentration increase inhibitors |
| 05/15/2007 | US7217687 Use of osteopontin for the treatment and/or prevention of neurologic diseases |
| 05/15/2007 | US7217535 Immunoassay diagnosis of susceptibility to atherosclerosis by analyzing blood for presence of enzyme using polyclonal or monoclonal antibodies; elevated levels are indicative of susceptibility |
| 05/15/2007 | US7217534 Methods of screening apoptosis modulating compounds, compounds identified by said methods and use of said compounds as therapeutic agents |
| 05/15/2007 | CA2392973C Benzoimidazole derivatives useful as antiproliferative agents |
| 05/15/2007 | CA2366829C Novel morpholine derivatives, method for the production thereof and pharmaceutical preparations containing said derivatives |
| 05/15/2007 | CA2087958C Transferrin binding proteins from neisseria gonorrhoeae and neisseria meningitidis |
| 05/10/2007 | WO2007053406A1 Combinations of antihypertensive and cholesterol lowering agents |
| 05/10/2007 | WO2007052843A1 Heterocyclic amide compound and use thereof |
| 05/10/2007 | WO2007052808A1 Hydrazide compound and thrombopoietin receptor activator |
| 05/10/2007 | WO2007052794A1 o-SUBSTITUTED ANILINE DERIVATIVE AND ANTIOXIDANT DRUG |
| 05/10/2007 | WO2007052561A1 Method for prevention of myocardial hypertrophy by inhibiting interaction between slim1 and usp, and agent for prevention of myocardial hypertrophy |
| 05/10/2007 | WO2007051920A1 Methanone compounds and the use thereof in pharmaceutical compositions, in particular for treating cardiovascular diseases |
| 05/10/2007 | WO2007051829A1 Oleuropein for the treatment of conditions associated to the peripheral vascular disease |
| 05/10/2007 | WO2007051317A1 Compositions and methods for treating atherosclerosis |
| 05/10/2007 | WO2007020286A3 Method of using potassium channel inhibiting compounds |
| 05/10/2007 | WO2007017894A3 PREPARATION OF NOVEL CRYSTALLINE η(ETA) FORM OF PERINDOPRIL ERBUMINE |
| 05/10/2007 | WO2007017893A3 Preparation of novel crystalline form of perindopril erbumine monohydrate |
| 05/10/2007 | WO2007006751A3 Use of bpi protein for the treatment of disorders of the metabolism and cardiovascular disorders |
| 05/10/2007 | WO2006120472A3 Novel beta-steroid compounds |
| 05/10/2007 | WO2006102395A3 Delivery systems and methods for diagnosing and treating cardiovascular diseases |
| 05/10/2007 | WO2005037278A3 Tbenazpril and amlodipine for reducing cardiovascular morbidity |
| 05/10/2007 | US20070106076 Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino [1,2-a] indoles |
| 05/10/2007 | US20070105958 Compounds for the treatment of metabolic disorders |
| 05/10/2007 | US20070105949 Intermediates for the preparation of lipoxin A4 analogs |
| 05/10/2007 | US20070105933 Amino alcohol compounds |
| 05/10/2007 | US20070105908 Thiazolimine compound and oxazolimine compound |
| 05/10/2007 | US20070105903 Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs |
| 05/10/2007 | US20070105901 Novel piperidine derivative |
| 05/10/2007 | US20070105899 Benzene compounds |
| 05/10/2007 | US20070105894 Combination of at least two compounds selected from an AT1-receptorantagonist or an ACE inhibitor or a HMG-Co-A reductase inhibitor |
| 05/10/2007 | US20070105889 Administering (S)-1-(2,3,7,8-tetrahydrofuro[2,3-g]indol-1-yl)-2-propylamine; serotonin receptor antagonists (5HT/5HT2C) for therapy of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea |
| 05/10/2007 | US20070105883 Novel physiologically active substances pf127oa, b and c substances |
| 05/10/2007 | US20070105868 3-(2-{5-methyl-2-[4-(trifluoromethyl)piperidin-1-yl]-1,3-thiazol-4-yl}ethoxy)phenyl]acetic acid,peroxime proliferator-activated receptor antagonists; side effect reduction; very low toxicity, especially hepatotoxicity; metabolic disorders; antidiabetic agents; anticholesterol agents; antilipemic agents |
| 05/10/2007 | US20070105860 Biphenylcarboxylic Amide Derivatives as p38 Kinase Inhibitors |
| 05/10/2007 | US20070105859 4-Phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (mek) inhibitors |
| 05/10/2007 | US20070105837 Novel derivatives of 4a,5,9,10,11,12-hexahydrobenzofuro[3a,3,2][2]-benzazepine, method for the production thereof and use thereof in the production of medicaments |
| 05/10/2007 | US20070105829 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation |
| 05/10/2007 | US20070105818 Water solubility, bioavailability, oral administration; unit dosage |
| 05/10/2007 | US20070104725 Use of modified extracellular matrix proteins in diagnosis and treatment of atherosclerosis |
| 05/10/2007 | US20070104702 Method for treating diseases associated with changes of qualitative and/quantitative composition of blood extracellular dna |
| 05/10/2007 | DE60119336T2 Verwendungen von thaliporphin oder seinen derivaten in der behandlung von herzkrankheiten und seine herstellung Uses of thaliporphine or its derivatives in the treatment of heart diseases and its production |
| 05/10/2007 | DE102006048362A1 Composition, useful to treat and/or protect disease condition e.g. circulatory disorder, comprises an active substance combination of isoflavone or isoflavone glycoside and a peptide derivative |
| 05/10/2007 | CA2628055A1 Polysaccharide-derived nitric oxide-releasing carbon-bound diazeniumdiolates |
| 05/10/2007 | CA2628014A1 Ortho-substituted aniline derivative and antioxidant drug |
| 05/10/2007 | CA2627423A1 Heterocycle substituted amide and sulfur amide derivatives as histone deacetylase (hdac) inhibitors |
| 05/09/2007 | EP1783227A1 Humanized anti-CCR2 antibodies and methods of use therefor |
| 05/09/2007 | EP1783215A1 Angiostatin and method of use for inhibition of angiogenesis |
| 05/09/2007 | EP1783127A1 Novel compound having lipase inhibitory activity |
| 05/09/2007 | EP1783126A2 N-oxides of N-phenyl-2-pyrimidine-amine derivatives |
| 05/09/2007 | EP1783113A2 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation |
| 05/09/2007 | EP1782825A2 Treatment of glycogen storage diseases type II |
| 05/09/2007 | EP1782821A1 Drug and method for improving brain function |
| 05/09/2007 | EP1782820A1 Method of screening toxin-neutralizing peptide, stx2 inhibitory peptide and vero toxin-neutralizing agent |
| 05/09/2007 | EP1782803A1 Coenzyme q10-containing composition |
| 05/09/2007 | EP1781775A1 Vascular stem cells and uses thereof |
| 05/09/2007 | EP1781657A2 Medicaments with hm74a receptor activity |